NovoCure Limited (FRA:038)
Germany
· Delayed Price · Currency is EUR | Market Cap | 1.13B |
| Revenue (ttm) | 547.41M |
| Net Income (ttm) | -151.41M |
| Shares Out | n/a |
| EPS (ttm) | -1.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 32 |
| Open | 9.84 |
| Previous Close | 9.08 |
| Day's Range | 9.84 - 9.84 |
| 52-Week Range | 8.63 - 32.57 |
| Beta | n/a |
| RSI | 46.04 |
| Earnings Date | Feb 26, 2026 |
About NovoCure
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was inc... [Read more]
Financial Performance
In 2024, NovoCure's revenue was $605.22 million, an increase of 18.82% compared to the previous year's $509.34 million. Losses were -$168.63 million, -18.55% less than in 2023.
Financial numbers in USD Financial StatementsNews
Novocure (NVCR) Appoints New CEO Amid Leadership Change
Novocure (NVCR) Appoints New CEO Amid Leadership Change
Novocure CEO Ashley Cordova Resigns; Frank Leonard Named Replacement
(RTTNews) - NovoCure Ltd. (NVCR), a Swiss medical devices and healthcare company, Monday announced that its chief executive officer, Ashley Cordova has resigned from the company.
Novocure Appoints Company President Frank Leonard as Chief Executive Officer
Novocure (NASDAQ: NVCR) today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective immediately. Mr. Leonard previously served as President of Novocure and succeeds As...
Novocure Appoints Company President Frank Leonard as Chief Executive Officer
BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective immediately. Mr. Leonard previously s...
NovoCure (NVCR) Q3 2025 Earnings Call Transcript
NovoCure (NVCR) Q3 2025 Earnings Call Transcript
Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the 37th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2, ...
2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon
A biotech upstart and a life sciences giant could be compelling additions to an investor's portfolio. NovoCure is a high-risk but potentially high-reward bet on industry-changing technology.
Novocure to Participate in 2025 Jefferies Global Healthcare Conference
Novocure (NASDAQ: NVCR) announced today that management will participate in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025. Ashley Cordova, Chief Executive Office...
Novocure to Participate in 2025 Jefferies Global Healthcare Conference
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025. As...
NovoCure Limited 2025 Q3 - Results - Earnings Call Presentation
Oversold Conditions For NovoCure (NVCR)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight
Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight
HC Wainwright & Co. Raises PT for NVCR, Maintains Buy Rating | NVCR Stock News
HC Wainwright & Co. Raises PT for NVCR, Maintains Buy Rating | NVCR Stock News
NovoCure Ltd (NVCR) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges
NovoCure Ltd (NVCR) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges
Novocure outlines four-indication expansion and profitability target for 2027 as GBM growth continues
NovoCure Limited (NVCR) Q3 2025 Earnings Call Transcript
Q3 2025 Novocure Ltd Earnings Call Transcript
Q3 2025 Novocure Ltd Earnings Call Transcript
NovoCure Ltd (NVCR) Q3 Earnings: EPS Loss of $0. ...
NovoCure Ltd (NVCR) Q3 Earnings: EPS Loss of $0.33 Beats Estimate, Revenue Surpasses Expectations at $167.2 Million
Novocure Reports Third Quarter 2025 Financial Results
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the third quarter that ended September 30, 2025. Novocure is a global oncology company working to exten...
NovoCure Q3 2025 Earnings Preview
JP Morgan Maintains Neutral Rating on NVCR, Lowers Price Target | NVCR Stock News
JP Morgan Maintains Neutral Rating on NVCR, Lowers Price Target | NVCR Stock News
NovoCure: Buy Rating As Pipeline Gains Drive Renewed Momentum
Novocure Limited (NVCR) is rated BUY, driven by expanding regulatory approvals, breakthrough clinical results, and a robust late-stage pipeline in cancer therapy. NVCR's Tumor Treating Fields technolo...
Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that it will present data at two upcoming oncology congresses, the 2025 European Association of Neuro-Oncology (EANO) Meetin...
Novocure to Report Third Quarter 2025 Financial Results
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2025 on October 30, 2025, before the U.S. financial markets open. Novocure management wi...
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced that final results from the Phase 3 METIS trial of Tumor Treating Fields (TTFields) therapy for brain metastases from non-small ce...